Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FJFS8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc. on January 6, 2026, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, which has an ultimate completion date of January 7, 2026, was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded on November 13, 2025, that positions the company as a regional prime vendor contractor supporting Department of Defense pharmaceutical supply needs through December 31, 2036.
DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, specializing in distributing comprehensive pharmaceutical products and medical consumables to federal agencies. The company's established performance across the PPV-G GEN V program reflects its capability to supply specialized pharmaceutical products, including oncology treatments, biologics, vaccines, and routine medications to military healthcare facilities worldwide. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FJFS8?
SPE2DR26FJFS8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FJFS8 worth?
The government has obligated $4,255 on SPE2DR26FJFS8.
Is contract SPE2DR26FJFS8 an order under another contract?
Yes. SPE2DR26FJFS8 is a delivery order under SPE2DR25D9157, an indefinite delivery contract.
Was contract SPE2DR26FJFS8 competed?
The extent of competition for SPE2DR26FJFS8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award